Is the use of antibiotic-impregnated external ventricular drainage beneficial in the management of iatrogenic ventriculitis? by Soleman, Jehuda et al.
CLINICAL ARTICLE
Is the use of antibiotic-impregnated external ventricular
drainage beneficial in the management of iatrogenic
ventriculitis?
Jehuda Soleman & Serge Marbacher & Javier Fandino &
Ali Reza Fathi
Received: 6 June 2011 /Accepted: 29 August 2011 /Published online: 18 September 2011
# Springer-Verlag 2011
Abstract
Background Profound evidence substantiates significantly
reduced risk of catheter-related infections with prophylactic
use of rifampin- and clindamycin-impregnated silicone cath-
eters (Bactiseal®, Codman Johnson & Johnson, Raynham,
MA, USA) for external ventricular drainage (EVD). However,
whether Bactiseal®-EVD (B-EVD) influences the treatment of
EVD-related ventriculitis remains controversial.
Methods We performed a retrospective analysis of patients
who developed ventriculitis after EVD or ventriculoperitoneal
(VP) shunt placement and consequently underwent either
placement of B-EVD (group 1) or a standard non-antibiotic-
impregnated EVD (group 2). Analyzed parameters included
demographic and clinical data, hospitalization time, time until
remission of the infection parameters, detection of new
bacterial resistance on antibiograms, and clinical outcome in
terms of the modified Rankin scale (mRS).
Results Time until remission of cerebrospinal fluid (CSF)
pleocytosis was significantly longer in patients undergoing B-
EVD (8±3.8 days; n=15; group 1) than in patients who
underwent standard EVD (5.1±1.8 days; n=10; group 2).
There was no significant difference between both groups for
the time until polymorphonuclear cells dropped below 50%
of peak value (5.8±1.6 vs. 4.1±2.9 days), CRP dropped
below 10 mg/l (4.2±3.5 vs. 5.6±3.3 days), the time of
plasma neutrophil remission (5.7±2.6 vs. 5.3±3.2 days) and
hospitalization time (28±12.5 vs. 35±19.4 days). The mRS
for both groups was 2. Development of new antibiotic
resistance did not occur in either group.
Conclusions This retrospective pilot study indicates that B-
EVD might have no major advantage in the management of
EVD or VP-shunt-related ventriculitis. Based on published
reports and the results of this study, data support only the
prophylactic use of B-EVD for prevention of EVD-related
infections. Prospective randomized clinical trials are warranted
to further evaluate the role of B-EVD in the treatment of
ventriculitis.
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Introduction
Rifampin- and clindamycin-impregnated silicone catheters
(Bactiseal®) for external ventricular drainage (EVD) were
developed to prevent cerebrospinal fluid (CSF) infections.
Various studies, including a prospective, randomized,
controlled trial [13], have shown a significantly reduced
risk of catheter-related infections with the use of Bactiseal-
EVD (B-EVD) [6, 8, 13]. Standard therapy with non-
antibiotic-impregnated EVD is known to have a high rate of
infection (5–20%) [2, 4–6, 9–11, 13]. Standard treatment of
CSF infection following EVD or VP shunt placement consists
of removal and/or exchange of the catheter and broad-
spectrum intravenous antibiotic agents until verification of
cultures [7]. Despite extensive data on the efficacy of B-EVD
in the prevention of CSF infections, it is still not clearly
J. Soleman : S. Marbacher : J. Fandino :A. R. Fathi (*)
Department of Neurosurgery, Kantonsspital Aarau,
Tellstrasse, 5001 Aarau, Switzerland
e-mail: AR.Fathi@gmx.net
S. Marbacher : J. Fandino :A. R. Fathi
Department of Intensive Care Medicine and Neurosurgery,
Bern University Hospital and University of Bern,
Bern, Switzerland
Acta Neurochir (2012) 154:161–164
DOI 10.1007/s00701-011-1156-5
defined whether B-EVD is beneficial after a CSF infection
has occurred.
The aim of our study was to analyze the efficacy of B-EVD
compared to standard non-antibiotic-impregnated EVD in the
treatment of EVD- and VP-shunt-related ventriculitis.
Methods
Weperformed a retrospective analysis of patients who received
a B-EVD (Codman, Johnson & Johnson, Raynham, MA,
USA) following the diagnosis of iatrogenic ventriculitis
between 2005 and 2006 (group 1), and compared the data to
a patient cohort that received standard non antibiotic-
impregnated EVD (Dispomedica GmbH, Hamburg, Germany)
between 2003 and 2005 (group 2). Diagnosis of iatrogenic
ventriculitis required at least one criterion A plus two criterions
B. A criterions were: fever >38.5°C, meningitis, irritability,
new neurologic deficit, decreased Glasgow Coma Scale,
increased white blood cells, increased CRP. B criterions were:
increased CSF white cells >300/mm2 (predominantly poly-
morphonuclear cells), elevated CSF protein and/or decreased
glucose, positive CSF Gram staining, positive CSF cultures.
Patients in both groups received broad-spectrum intra-
venous antibiotics until the microorganisms were identified
in cultures and the antibiogram results were completed. The
antibiotic regimen was then specifically targeted until
cultures were negative and clinical parameters of infection
were in a normal range.
The following data were acquired for statistical analyses:
demographic and clinical data, hospitalization time, time until
remission of the infection parameters, detection of new
bacterial resistance after insertion of a B-EVD on antibio-
grams, and clinical outcome using the mRS. Patients with
incomplete patient records and patients with initial Gram-
negative infections were excluded from the analysis, since B-
EVD is ineffective in treating Gram-negative infections.
Analysis of the final data set was performed using JMP
software (SAS Institute Inc., Cary NC, USA). Values were
expressed as mean ± SD. A p value <0.05 was considered
significant.
Results
Twenty-five patients (13 male, 12 female) were included in
the study (15 in group 1, ten in group 2). The mean ages in
groups 1 and 2 were 51.5±11.4 years and 50±19.8 years,
respectively. Patients in group 1 underwent ventriculostomy
for EVD due to subarachnoid hemorrhage (n=6), normal
pressure hydrocephalus (n=2), intraventricular hemorrhage
(n=1) and congenital hydrocephalus (n=1). EVD became
necessary in group 2 due to subarachnoid hemorrhage (n=
10), normal pressure hydrocephalus (n=2), congenital
hydrocephalus (n=2) and obstructive hydrocephalus (n=1).
We observed that time to remission of pleocytosis was
significantly longer in group 1 (8±3.8 days) than in group 2
(5.1±1.8 days) (p<0.05). The polymorphonuclear cells
decreased below 50% of peak value significantly faster in
group 1 than in group 2 (4.1±2.9 vs. 5.8±1.6 days; p<0.05).
There were no significant differences between group 1 and
group 2 for the time until plasma neutrophil remission (5.7±
2.6 vs. 5.3±3.2 days) and for the time until C-reactive
protein (CRP) dropped below 10 mg/l (4.2±3.5 vs. 5.6±
3.3 days). An overview of the course of laboratory infection
parameters in both groups is given in Table 1.
The length of hospitalization from the diagnosis of
EVD-related ventriculitis until discharge was 28±12.5 days
in group 1 and 35±19.4 days in group 2 (n.s.). The mRS of
both groups was 2 (Table 2).
Table 1 Course of infection
parameters (CRP C-reactive
protein)
Group 1;
Standard EVD
Group 2;
B-EVD
Time until remission of pleocytosis (days) 5.1 8 p=0.044
Time until polymorphonuclear cells <50% (days) 4.1 5.8 n.s.
Time until plasma neutrophils <10 (days) 5.3 5.7 n.s.
Time until CRP <10 (days) 5.6 4.2 n.s.
Table 2 Comparison of
hospitalization time in days
and mRS
Group 1; Standard EVD Group 2; B-EVD
Hospitalization time (days) 35 28 n.s.
Modified Rankin scale 2 2 n.s.
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The analysis of the clinical data and antibiograms for the B-
EVD revealed no development of new antibiotic resistance.
Discussion
CSF infections, i.e., meningitis and ventriculitis, are the most
common complications caused by EVD and VP shunts [4].
They are associated with increased morbidity, mortality, and
hospitalization time [13]. Concerns regarding the risks of CSF
infection have led to widespread use of prophylactic antibiotic
agents in the treatment of patients with EVD catheters. It has
been shown that prophylaxis with a single broad-spectrum
antibiotic agent (cefepime) was an effective alternative to
dual-specific antibiotic treatment with ampicillin/sulbactam
and aztrenam for patients with an EVD in situ [12]. An
additional study demonstrated almost identical rates of CSF
infection in patients who received prophylactic antibiotics
throughout the period the EVD catheter was in place (3.8%)
compared to patients who received only periprocedural
antibiotics (4%) [1]. However, evidence-based guidelines for
prophylactic antibiotic (PAB) administration do not yet exist,
and the effectiveness of PAB was not proven in a randomized,
placebo-controlled, multicenter, double-blind study [7]. Given
the clinical results with central line catheters impregnated with
antibiotic agents [3] and the lack of data on PAB effective-
ness, clinical trials with impregnated EVD catheters were
conducted. It has been shown that with prophylactic use of B-
EVD, risk of catheter-related infections can be significantly
reduced [6, 13]. The standard treatment for CSF infections
due to EVD or VP shunt insertion is changing the drainage
system and treatment with antibiotic agents. To date, there is
no study comparing insertion of B-EVD with non-antibiotic-
impregnated EVD in the management of EVD- or VP-shunt-
associated CSF infection.
In the presented study, we analyzed the efficacy of B-EVD
compared to standard EVD in the course of iatrogenic
ventriculitis (EVD-related infections, VP shunt infections).
One would expect greater efficacy using B-EVD, since it has
been proven to significantly reduce catheter-related infections.
Surprisingly, our study demonstrated no significant differences
in the efficacy of treatment with B-EDVand standard EVD, in
terms of parameters related to the course of infection (with the
exception of remission of pleocytosis), hospitalization time,
and outcome.
Despite the limited number of patients, our study suggests
that there is limited benefit in using B-EVD for the
management of iatrogenic ventriculitis. Additionally, in the B-
EVD group, the period until normalization of CSF pleocytosis
is significantly longer (p<0.05), suggesting that the duration of
the infection is not shortened by B-EVD. All other infection
parameters analyzed (time of plasma neutrophil remission,
decrease in polymorphonuclear cells below 50% of peak
value, and time until CRP dropped below 10 mg/l) showed no
significant difference. The hospitalization time of patients
treated with B-EVD tends to be shorter, but not significantly.
The costs of B-EVD exceed those of standard EVD by
44.1%. In addition, the hospitalization time of patients
treated with B-EVD tends to be shorter (mean hospitaliza-
tion time B-EVD group 28±12.5, standard EVD group 35±
19.4 days), but not significantly. Therefore, we assume that
the usage of B-EVD in the management of iatrogenic
ventriculitis might not have an economical advantage
compared to standard EVD.
Antimicrobial resistance is an issue of potential concern
with the use of impregnated catheters. Although there is no
evidence that such resistance has resulted from central venous
line catheters, continued surveillance for antibiotic resistance
is required [3, 13]. None of the patients in our study treated
with B-EVD showed new antibiotic resistance.
In conclusion, this retrospective pilot study indicates that
B-EVD has no major advantage over non-antibiotic-
impregnated catheters in the management of EVD-related
ventriculitis. Based on these findings, the indication for use
of B-EVD remains prevention rather than management of
EVD-associated infections. Prospective randomized clinical
trials are warranted to further evaluate the effect of B-EVD
in the management of iatrogenic ventriculitis.
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Comment
The assumption that the use of EVD catheters impregnated with
antibiotics—supported logically by the industry—can significantly
reduce the risk of catheter-related infections has progressively been
established in last decades. Nevertheless, it was recently demonstrated
that the risk of false-negative culture results may be increased when a
CSF sample is drawn through an antibiotic impregnated catheter. In
fact, when managing a known shunt infection, a false-negative result
from an EVD culture specimen may lead to an inappropriate duration
and type of antibiotic therapy, certainly playing a noteworthy role in
the actual emergence of resistant bacteria. The present well-written
retrospective study, despite the small number of patients, provides
considerable clinical implications, mostly related to the widespread
use of antibiotic-impregnated drains and the current high rates of shunt
reinfection after EVD use worldwide. Particularly interesting is the
fact that there were no significant differences in the efficacy of
treatment with antibiotics-impregnated EDV and standard EVD, in
terms of parameters related to the course of infection (except for
remission of pleocytosis), hospitalization time, and outcome. These
results are similar to our personal observations. In fact, in a
consecutive series of 29 patients with antibiotics-impregnated EVD
compared to a comparable control group, we have documented
analogous results. The authors should be complimented for their
efforts in reporting their experience in this, often-neglected, field; this
study should be considered for future prospective randomized clinical
trials in further evaluating the real advantages (or disadvantages) of
the antibiotic-impregnated catheters.
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